Karyopharm Therapeutics | KPTI - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 6.57B 2.82B 2026-06
Abbott USD 6.8B 1.72B 2026-03
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Incyte USD 3.98B 33.45M 2026-06
J&J USD 20.42B 1.27B 2026-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Merck USD 6.85B 1.52B 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Novartis USD 7.62B 739M 2026-06
Novartis USD 6.88B 2.68B 2026-03
Pfizer USD 976M 727M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Takeda JPY 460.98B 134.07B 2026-06
Tectonic Therapeutic USD 236.89M 16.9M 2026-03
TG Therapeutics USD 612.25M 170.04M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Xencor USD 44.66M 30.49M 2026-06